MedTrace Logo

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

NCT00539526 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues

Conditions

Interventions

DRUG

Bimatoprost 0.03%

bimatoprost 0.03%, 1 drop nightly for 3 months

DRUG

travoprost 0.004%

travoprost 0.004% eye drops, 1 drop nightly for 3 months

DRUG

latanoprost 0.005% eye drops

latanoprost 0.005%, 1 drop nightly for 3 months

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539526 on ClinicalTrials.gov